- Home
- WHWK vs FBIO Comparison
WHWK vs FBIO Comparison
Compare WHWK & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- FBIO
- Stock Information
- Founded
- WHWK 2007
- FBIO 2006
- Country
- WHWK United States
- FBIO United States
- Employees
- WHWK N/A
- FBIO N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- WHWK Health Care
- FBIO Health Care
- Exchange
- WHWK Nasdaq
- FBIO Nasdaq
- Market Cap
- WHWK 48.3M
- FBIO 49.1M
- IPO Year
- WHWK N/A
- FBIO N/A
- Fundamental
- Price
- WHWK $1.68
- FBIO $1.78
- Analyst Decision
- WHWK
- FBIO Strong Buy
- Analyst Count
- WHWK 0
- FBIO 3
- Target Price
- WHWK N/A
- FBIO $21.00
- AVG Volume (30 Days)
- WHWK 172.0K
- FBIO 144.0K
- Earning Date
- WHWK 05-08-2025
- FBIO 05-27-2025
- Dividend Yield
- WHWK N/A
- FBIO N/A
- EPS Growth
- WHWK N/A
- FBIO N/A
- EPS
- WHWK 0.91
- FBIO N/A
- Revenue
- WHWK $27,775,000.00
- FBIO $57,675,000.00
- Revenue This Year
- WHWK $30.85
- FBIO $63.20
- Revenue Next Year
- WHWK N/A
- FBIO $66.70
- P/E Ratio
- WHWK $1.87
- FBIO N/A
- Revenue Growth
- WHWK 16.51
- FBIO N/A
- 52 Week Low
- WHWK $1.21
- FBIO $1.33
- 52 Week High
- WHWK $3.81
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- WHWK N/A
- FBIO 54.00
- Support Level
- WHWK N/A
- FBIO $1.60
- Resistance Level
- WHWK N/A
- FBIO $1.76
- Average True Range (ATR)
- WHWK 0.00
- FBIO 0.10
- MACD
- WHWK 0.00
- FBIO -0.00
- Stochastic Oscillator
- WHWK 0.00
- FBIO 44.69
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.